
 
 
 
 
 "The closing of the business swap between Boehringer Ingelheim and Sanofi in India is a significant milestone for both the organisations. Through this strategic transaction, we further strengthen our commitment towards providing greater value to our customers,"   Managing Director   said. SM RSY
